Mesa Laboratories third quarter revenues increase 18% to $11,361,000

Published on February 5, 2013 at 11:38 PM · No Comments

Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today reported an 18 percent increase in revenues for the third quarter ended December 31, 2012.

Highlights:  

  • Revenues for the third quarter increased 18 percent to $11,361,000 as compared to the same quarter last year
  • Revenues for the nine months ended December 31, 2012 increased 17 percent to $33,627,000 as compared to the same period last year
  • Net income for the nine months ended December 31, 2012 increased three percent to $5,891,000 as compared to the same period last year
  • Non-GAAP adjusted net income for the nine months ended December 31, 2012 increased 11 percent to $7,144,000 as compared to the same period last year

Revenues for the third quarter increased 18 percent to $11,361,000 as compared to $9,650,000 for the same quarter last year.  Net income for the third quarter decreased 22 percent to $1,543,000 or $0.44 per diluted share of common stock as compared to $1,987,000 or $0.57 per diluted share of common stock for the same quarter last year.  Net income for the third quarter was impacted by $526,000, before tax, of Chief Financial Officer transition costs, which are one-time in nature.

Revenues for the nine months ended December 31, 2012 increased 17 percent to $33,627,000 as compared to $28,648,000 for the same period last year.  Net income for the nine months ended December 31, 2012 increased three percent to $5,891,000 or $1.67 per diluted share of common stock as compared to $5,720,000 or $1.66 per diluted share of common stock for the same period last year.

On a non-GAAP basis (which excludes acquisition related intangible amortization, net of tax effects), adjusted net income for the third quarter decreased 11 percent to $1,974,000 or $0.56 per diluted share of common stock as compared to $2,217,000 or $0.63 per diluted share of common stock for the same quarter last year.  Adjusted net income for the third quarter was impacted by $526,000, before tax, of Chief Financial Officer transition costs, which are one-time in nature.  Adjusted net income for the nine months ended December 31, 2012 increased 11 percent to $7,144,000 or $2.03 per diluted share of common stock as compared to $6,427,000 or $1.86 per diluted share of common stock for the same period last year.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
(optional)
Post